Search research articles
Contact Us
Filters
Showing results (11-20 of 37) with videos related to
Page
of 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2010
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer
Kimberly L Blackwell, Harold J Burstein, Anna Maria Storniolo, et al.
The New England Journal of Medicine
|
June 2, 2015
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
Nicholas C Turner, Jungsil Ro, Fabrice André, et al.
Chinese Journal of Cancer
|
November 25, 2014
Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting
Feng Roger Luo, Jian Ding, Helen X Chen, et al.
Nature Communications
|
March 3, 2018
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
Ben O'Leary, Sarah Hrebien, James P Morden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2023
Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib
Ezra Rosen, Timothy A Yap, Elizabeth K Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2010
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents
Janet E Dancey, Kevin K Dobbin, Susan Groshen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2008
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer
Angelo Di Leo, Henry L Gomez, Zeba Aziz, et al.
NPJ Precision Oncology
|
July 7, 2025
Exceptional response to the ATR inhibitor, camonsertib, in a patient with ALT+ metastatic melanoma
Natalie Y L Ngoi, Ian M Silverman, Adrienne Johnson, et al.
The Journal of Molecular Diagnostics : JMD
|
March 21, 2023
Detection of Biallelic Loss of DNA Repair Genes in Formalin-Fixed, Paraffin-Embedded Tumor Samples Using a Novel Tumor-Only Sequencing Panel
Dominik Glodzik, Pier Selenica, Ryan A Rogge, et al.
Scientific Reports
|
May 27, 2017
Erratum: Enzyme discovery beyond homology: a unique hydroxynitrile lyase in the Bet v1 superfamily
Elisa Lanfranchi, Tea Pavkov-Keller, Eva-Maria Koehler, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 37) with videos related to
Sort By:
Page
of 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2010
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer
Kimberly L Blackwell, Harold J Burstein, Anna Maria Storniolo, et al.
The New England Journal of Medicine
|
June 2, 2015
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
Nicholas C Turner, Jungsil Ro, Fabrice André, et al.
Chinese Journal of Cancer
|
November 25, 2014
Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting
Feng Roger Luo, Jian Ding, Helen X Chen, et al.
Nature Communications
|
March 3, 2018
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
Ben O'Leary, Sarah Hrebien, James P Morden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2023
Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib
Ezra Rosen, Timothy A Yap, Elizabeth K Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2010
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents
Janet E Dancey, Kevin K Dobbin, Susan Groshen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2008
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer
Angelo Di Leo, Henry L Gomez, Zeba Aziz, et al.
NPJ Precision Oncology
|
July 7, 2025
Exceptional response to the ATR inhibitor, camonsertib, in a patient with ALT+ metastatic melanoma
Natalie Y L Ngoi, Ian M Silverman, Adrienne Johnson, et al.
The Journal of Molecular Diagnostics : JMD
|
March 21, 2023
Detection of Biallelic Loss of DNA Repair Genes in Formalin-Fixed, Paraffin-Embedded Tumor Samples Using a Novel Tumor-Only Sequencing Panel
Dominik Glodzik, Pier Selenica, Ryan A Rogge, et al.
Scientific Reports
|
May 27, 2017
Erratum: Enzyme discovery beyond homology: a unique hydroxynitrile lyase in the Bet v1 superfamily
Elisa Lanfranchi, Tea Pavkov-Keller, Eva-Maria Koehler, et al.
Page
of 4